glp-1 mimetics Clinical Focus on Agonists in Type 2 Diabetes Mellitus Glucagon-like peptide-1 and glucose-dependent insulinotropic

Abbreviations DPP-IV, Dipeptidyl-Peptidase 4

Based on cohort studies of patients with obesity (irrespective of diabetes status) who were newly started on tirzepatide or semaglutide, tirzepatide is associated with significantly more weight loss than semaglutide [102]

Cardiovascular Protection With Sodium-Glucose Co-Transporter-2 Inhibitors in Type 2 Diabetes: Does it Apply to All Patients

The court separated the NAION lawsuits from the existing GLP-1 gastrointestinal injury MDL, recognizing NAION as a distinct injury that requires focused judicial review

Safety, Side Effects, and Clinical Considerations Before Starting Semaglutide Safety remains a central consideration in any medically guided weight loss program

For most individuals scrolling through social media advertisements, distinguishing an FDA-approved drug from a compounded product can be almost impossible